ライフサイエンスコーパス: risk ratio

1 formulation as having a positive benefit-to-risk ratio.

2 more tangible for policymakers compared with risk ratios.

3 usception deaths and most favourable benefit-risk ratios.

4 ivariate and multivariate analysis estimated risk ratios.

5 All effects were estimated as risk ratios.

6 who received the minimally invasive surgery (risk ratio 0.29; 95% confidence interval 0.11-0.80; P =

7 A longer AL (per millimeter increase) (risk ratio 0.58 [95% confidence interval 0.38-0.88) was

8 mia was higher for LRYGB than LSG at 1 year (risk ratio 0.58, 95% CI 0.46-0.73, P < 0.001; moderate c

9 moderate certainty of evidence) and 5 years (risk ratio 0.68, 95%CI 0.46-0.99, P = 0.04; low certaint

10 -cause hospitalizations (11.2% versus 14.0%; risk ratio 0.80 [95% CI, 0.65-0.98], P value 0.035).

11 f 318 infants in the placebo group (adjusted risk ratio 0.85 [95% CI 0.62-1.15]).

12 ts with at least one exacerbation decreased (risk ratio 0.85, 0.74 to 0.97; p=0.015).

13 ated with functional outcome overall (pooled risk ratio 0.87, 95% CI 0.71 to 1.06), but were signific

14 PIE group 83.3% versus standard group 84.7%; risk ratio 0.98 [95% confidence interval (CI) 0.90 to 1.

15 s observed, n = 7380): cumulative mortality (risk ratio 0.99, 95% confidence interval [CI] 0.95-1.03,

16 were 15.0% with PN and 40.9% with Controls (risk ratio = 0.43, 95% CI = 0.30 to 0.60, p < 0.001).

17 73 - 0.95]) and butyrate-producers (adjusted risk ratio = 0.82 [95% CI: 0.67 - 0.97]).

18 wer richness of obligate anaerobes (adjusted risk ratio = 0.84[95% CI: 0.73 - 0.95]) and butyrate-pro

19 oup vs 219/648 [33.8%] in the control group; risk ratio = 0.95; 95% CI, 0.82-1.10; p = 0.49; I = 0%).

20 ed with 22 of 78 (28.2%) in the CQ-only arm (risk ratio, 0.146 [95% confidence interval, .046-.467];

21 whereas 3.1% and 14.6% had very poor sleep (risk ratio, 0.21; 95% CI, 0.06-0.71), respectively.

22 ignificant improvement in patients' anxiety (risk ratio, 0.32 [0.12, 0.86]; p = 0.02; n = 2 studies)

23 6]; p = 0.02; n = 2 studies) and depression (risk ratio, 0.39 [0.17-0.87]; p = 0.02; n = 2 studies) s

24 o, 0.54 [95% CI, 0.41-0.70]; for >5 minutes, risk ratio, 0.41 [95% CI, 0.32-0.53]).

25 linical Severity Score >=8: 6.6% versus 14%; risk ratio, 0.46; 95% CI, 0.24-0.87; P=0.013).

26 ional balloon angioplasty participants died (risk ratio, 0.48; 95% CI: 0.04, 5.10).

27 val (reference, <2 minutes; for 2-5 minutes, risk ratio, 0.54 [95% CI, 0.41-0.70]; for >5 minutes, ri

28 llalta scale >=15 or ulcer: 8.7% versus 15%; risk ratio, 0.57; 95% CI, 0.32-1.01; P=0.048; and Venous

29 (26.6%) receiving aspirin plus clopidogrel (risk ratio, 0.57; 95% confidence interval [CI], 0.42 to

30 01), and coma days decreased from 14% to 9% (risk ratio, 0.5; 95% CI, 0.4-0.6; p < 0.001).

31 2.6% (44 of 1704 pregnancies), respectively (risk ratio, 0.60; 95% CI, 0.37 to 0.96).

32 5.1%) and 83 patients (24.9%), respectively (risk ratio, 0.61; 95% CI, 0.44 to 0.83; P = 0.005).

33 iving oral anticoagulation plus clopidogrel (risk ratio, 0.63; 95% confidence interval [CI], 0.43 to

34 nts (21.7%) and in 53 (34.0%), respectively (risk ratio, 0.64; 95% CI, 0.44 to 0.92; P = 0.02).

35 uction in postoperative atrial fibrillation (risk ratio, 0.64; 95% CI, 0.52-0.78; p < 0.0001), ICU st

36 illalta scale >=10 or ulcer: 18% versus 28%; risk ratio, 0.65; 95% CI, 0.45-0.94; P=0.021) or severe

37 s; 95% CI for noninferiority, -25.0 to -3.6; risk ratio, 0.69; 95% CI for superiority, 0.51 to 0.92).

38 of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [95% CI, 0.57 to 0.92]; absolute risk d

39 for noninferiority, -14.9 to -1.5; P<0.001; risk ratio, 0.74; 95% CI for superiority, 0.57 to 0.95;

40 c stress disorder symptoms with ICU diaries (risk ratio, 0.75 [0.3-1.73]; p = 0.5; n = 3 studies); ho

41 ts; 95% CI for noninferiority, -11.9 to 4.0; risk ratio, 0.77; 95% CI for superiority, 0.46 to 1.31).

42 0 of 1684 pregnancies) in the placebo group (risk ratio, 0.77; 95% confidence interval [CI], 0.56 to

43 al mortality (four vs three deaths; relative risk ratio, 0.7; 95% CI, 0.2-3.2; p = 0.717), all placeb

44 for bradycardia had a 19% lower likelihood (risk ratio, 0.81 [95% CI, 0.70, 0.93]; P=0.004) of survi

45 matic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]

46 ent of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40).

47 n 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55).

48 decreased return of spontaneous circulation (risk ratio, 0.87; 95% CI, 0.77-0.98) and survival to adm

49 .6%) in the slower-increment group (adjusted risk ratio, 0.88; 95% CI, 0.68 to 1.16).

50 5% CI, 0.77-0.98) and survival to admission (risk ratio, 0.88; 95% CI, 0.78-0.99) when compared with

51 t associated with a difference in mortality (risk ratio, 0.90; 95% CI, 0.74-1.10; p = 0.31), acute ki

52 (difference, -2.3% [95% CI, -5.9% to 1.4%]; risk ratio, 0.93 [95% CI, 0.83 to 1.04]; P = .23).

53 ipients of intraosseous amiodarone (adjusted risk ratio, 0.94 [95% CI, 0.66-1.32]) or intraosseous li

54 treatments (magnesium: 1.49, placebo: 1.59; risk ratio, 0.94 [95% CI, 0.79 to 1.11]; P = .47).

55 o significant improvement in either anxiety (risk ratio, 0.94; 95% [0.66-1.33]; p = 0.72) or depressi

56 e >=5 or ulcer: 49% PCDT versus 51% No-PCDT; risk ratio, 0.95; 95% CI, 0.78-1.15; P=0.59).

57 .1%) in the slower-increment group (adjusted risk ratio, 0.96; 95% CI, 0.86 to 1.07).

58 ) assigned to the slower increment (adjusted risk ratio, 0.96; 95% confidence interval [CI], 0.92 to

59 (difference, -1.3% [95% CI, -6.8% to 4.2%]; risk ratio, 0.97 [95% CI, 0.84-1.11]; P = .64).

60 4; 95% [0.66-1.33]; p = 0.72) or depression (risk ratio, 0.98; 95% [0.5-1.9]; p = 0.95) in relatives.

61 for noninferiority, -4.7 to 4.3; P = 0.004; risk ratio, 0.98; 95% CI for superiority, 0.62 to 1.55;

62 left ventricular unloading while on VA-ECMO (risk ratio: 0.79; 95% confidence interval: 0.72 to 0.87;

63 , 88.1-94.1) of 631 in the rapid ART period (risk ratio 1.01, 95% CI 0.92-1.11).

64 237 patients in the intravenous iron group (risk ratio 1.03, 95% CI 0.78-1.37; p=0.84).

65 ved an mRS score of 0-2 at 90 days (adjusted risk ratio 1.04, 95% CI 0.96-1.14; p=0.35).

66 had viral loads less than 400 copies per mL (risk ratio 1.32, 95% CI 1.04-1.68; p=0.045).

67 events [2%] among 1265 in the control group; risk ratio 1.63 [1.01 to 2.67]; risk difference 1.21 [0.

68 with 50 (43%) of 117 in the efavirenz group (risk ratio 1.64, 95% CI 1.31-2.06).

69 evident at the end of the treatment period (risk ratio 1.91, 1.46 to 2.49; p<0.0001).

70 ensus tracts lacking such current privilege (risk ratio = 1.01, 95% confidence interval: 0.94, 1.08).

71 tly privileged areas that had been redlined (risk ratio = 1.17, 95% confidence interval: 1.06, 1.29),

72 posure-induced mediator-outcome confounders: risk ratio = 1.85 (95% confidence interval: 1.06, 3.24),

73 nce, 0.0% [95% CI, -8.9% to -8.9%]; adjusted risk ratio, 1.03 [95% CI, 0.66-1.61]; P = .89).

74 6-1.32]) or intraosseous lidocaine (adjusted risk ratio, 1.03 [95% CI, 0.74-1.44]).

75 nt arms (493/1,142 [43%] vs 486/1,067 [46%]; risk ratio, 1.04; 95% CI, 0.97-1.12; p = 0.27; I = 1%).

76 e H2RB group died at the hospital by day 90 (risk ratio, 1.05 [95% CI, 1.00 to 1.10]; absolute risk d

77 orted fair to poor health (10-year mortality risk ratio, 1.06 [CI, 0.82 to 1.37]).

78 onsignificant higher relative risk in women (risk ratio, 1.07 [0.98-1.17]).

79 .0% in 2010 to 1.5% in 2017; adjusted annual risk ratio, 1.07; 95% confidence interval, 1.04-1.09).

80 (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to

81 m 2010 (3.1%) to 2017 (6.4%; adjusted annual risk ratio, 1.12; 95% confidence interval, 1.12-1.13).

82 nical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27).

83 ence of severe hypoxemia was 20.6% vs 17.6% (risk ratio, 1.17; 95% CI, 0.90-1.51; P = .99) and need f

84 % of patients, respectively, had a response (risk ratio, 1.20; 95% confidence interval, 0.95 to 1.51)

85 .5-9.5]) and intravenous lidocaine (adjusted risk ratio, 1.21 [95% CI, 1.02-1.45]; adjusted absolute

86 ailable (432/1,375 [31%] vs 330/1,295 [25%]; risk ratio, 1.24; 95% CI, 1.10-1.39; p = 0.0004; I = 0%)

87 cipients of intravenous amiodarone (adjusted risk ratio, 1.26 [95% CI, 1.06-1.50]; adjusted absolute

88 e remission of type 2 diabetes (86% vs. 53%; risk ratio, 1.27; 95% CI, 1.03 to 1.57) and of hypertens

89 to 1.67]) and a 30% higher risk at year 13 (risk ratio, 1.30 [CI, 1.18 to 1.42]).

90 than ranibizumab (39.9% vs. 31.7%; adjusted risk ratio, 1.30; 95% CI, 1.07-1.57; P = 0.009).

91 onin and placebo groups had very good sleep (risk ratio, 1.33; 95% CI, 0.94-1.89), whereas 3.1% and 1

92 interventions improved medication adherence (risk ratio, 1.34; CI, 1.12-2.56; I = 75%) and self-monit

93 need for rescue strategy was 19.7% vs 14.6% (risk ratio, 1.35; 95% CI, 1.02-1.79; adjusted P = .54) i

94 % CI, 1.68-3.72), and survival to discharge (risk ratio, 1.44; 95% CI, 1.11-1.86).

95 higher cumulative risk for death at year 10 (risk ratio, 1.46 [95% CI, 1.27 to 1.67]) and a 30% highe

96 3 to 1.57) and of hypertension (68% vs. 41%; risk ratio, 1.51; 95% CI, 1.21 to 1.88).

97 tumor and personal characteristics (adjusted risk ratio, 1.5; P = 0.08).

98 at baseline (for example, 10-year mortality risk ratio, 1.62 [CI, 1.37 to 1.90]) but not among those

99 these groups widened between 2004 (adjusted risk ratio, 1.72 [95% CI, 1.71-1.73]) and 2017 (adjusted

100 associated with greater risk of amputation (risk ratio, 1.80; 95% confidence interval, 1.07-3.01), a

101 1.72 [95% CI, 1.71-1.73]) and 2017 (adjusted risk ratio, 1.83 [95% CI, 1.82-1.83]) (P < .001 for inte

102 Black race (relative risk ratio, 1.98; 95% confidence interval [CI], 1.07-3.6

103 pressure in adulthood (odds ratios, 1.1-4.5; risk ratios, 1.45-3.60; hazard ratios, 2.8-3.2).

104 birth weight, and smoking during pregnancy (risk ratio = 2.47, 95% confidence interval: 1.31, 4.66),

105 positive than in CrAg-negative participants (risk ratio, 2.2; 95% CI, 1.7-2.9; P < .001).

106 g's asthma without nasal allergies (relative risk ratio, 2.31 [95% CI, 1.23-4.33]).

107 2.82-3.89), survival to hospital admission (risk ratio, 2.50; 95% CI, 1.68-3.72), and survival to di

108 -nonfrail transition, and diabetes (relative risk ratio, 2.56; 95% CI, 1.22-5.39) was associated with

109 2.56; I = 75%) and self-monitoring behavior (risk ratio, 2.58; CI, 1.56-4.27; I = 0%) up to 12 mo pos

110 olute increase and a 173% relative increase (risk ratio, 2.73; 95% CI, 2.45-3.04) in baseline laborat

111 evere chronic obstructive pulmonary disease (risk ratio, 2.89; 95% confidence interval, 1.80-4.65) or

112 valuation, ++--) and lesion clearance rates (risk ratio, 2.97; 95% confidence interval = 2.45-3.59; 4

113 r were, respectively, 24- and 6-fold higher (risk ratios, 24 [95% confidence interval {CI}, 10.8-62.3

114 index, smoking during pregnancy, and parity (risk ratio = 3.02, 95% confidence interval: 1.26, 7.25).

115 ence interval, 1.80-4.65) or breathlessness (risk ratio, 3.07; 95% confidence interval, 2.16-4.37) at

116 increased return of spontaneous circulation (risk ratio, 3.09; 95% CI, 2.82-3.89), survival to hospit

117 PSE compared with neither (adjusted relative risk ratio = 4.16, 95% confidence interval = 1.34-12.85)

118 in a Plasmodium-positive household in 2017 (Risk Ratio, 5.00 [95% confidence interval, 2.09-11.96],

119 ut six times that of the general population (risk ratio 6.14, 95% CI 4.95-7.62; p<0.0001).

120 rtial clearance rates compared with placebo (risk ratio, 7.12; 95% confidence interval = 4.36-11.64;

121 ighest participant complete clearance rates (risk ratio, 7.73; 95% confidence interval = 3.21-18.61;

122 eased by 10% per log level of TTV copies/mL (risk ratio, .90 [95% confidence interval, .84-.97]; P =

123 iated with an increased risk of fatty liver (risk ratio [95% confidence interval], 1.42 [1.18-1.70];

124 We calculated adjusted risk ratios according to MS status and relapse(s) in the

125 rifampin resistance, we calculated adjusted risk ratios (adjRRs) and 95% confidence intervals (CIs)

126 34 participants (45%) in the placebo group (risk ratio after multiple imputation for missing respons

127 ts, and logistic regression models estimated risk ratios and (99% confidence intervals).

128 tic regression models, and marginal adjusted risk ratios and 95% CIs were estimated to describe facto

129 Risk ratios and 95% credible interval were calculated.

130 mial regression models were used to estimate risk ratios and their 95% confidence intervals.

131 d to treat for benefit and harm, the benefit-risk ratio, and Incremental Net Benefit.

132 stimated adjusted risk differences, adjusted risk ratios, and 95% confidence intervals for the associ

133 estimated the 5-year risks of death, 5-year risk ratios, and decrease in lifespan within 5 years ass

134 ns during pregnancy (Truven Health: adjusted risk ratio (aRR) = 1.22, 95% confidence interval (CI): 1

135 AT was 79% compared to 68% with 4R (adjusted risk ratio (aRR) of 1.17 [95% CI 1.17-1.27, p<0.0001]).

136 = 14,906 versus 54.5%, n = 21,403, adjusted risk ratio [aRR] 1.2, 95% CI 1.1-1.2, p < 0.001) and wer

137 Starting undetectable (adjusted risk ratio [aRR] 1.39; 1.28-1.52) and enrolling in QHPs

138 e HIVST + $3 (geometric mean 40.9%, adjusted risk ratio [aRR] 3.01 [95% CI 1.63-5.57], p < 0.001), HI

139 s was strongly associated with LBW (adjusted risk ratio [aRR] = 3.42, P = .02) and SGA (aRR = 4.24, P

140 I]: .36-1.36; I2 = 64.5%, P = .006; adjusted risk ratio [aRR] from 3 studies = 0.66, 95% CI: .20-2.24

141 onceptional HbA1c level below 6.5% (adjusted risk ratio [aRR] vs. women without T1D, 2.83 [95% CI, 2.

142 wer richness of obligate anaerobes (adjusted risk ratio [aRR], 0.84; 95% confidence interval [CI], .7

143 Starting undetectable (adjusted risk ratio [aRR], 1.39; 1.28-1.52) and enrolling in QHPs

144 Vehicle ownership (multivariable-adjusted risk ratio [aRR], 1.58) increased the risk of CHIKV infe

145 ge categories, with an age-adjusted relative risk ratio (aRRR) of 2.5 (95% confidence interval [CI] 2

146 djusted risk differences (ARDs) and adjusted risk ratios (ARRs) with 95% confidence intervals (CIs) w

147 rrespective of mental illness type (adjusted risk ratios [ARRs] varied from 1.7-3.1, all p < 0.001).

148 om 0.65 to 0.89, and total Observed:Expected risk ratios between 0.94 and 1.00.

149 Risk ratios compared with placebo for all-cause disconti

150 Average risk ratio comparing 30-day composite outcome of all-cau

151 The risk ratio controls vs study infants was 8.3 (95% CI, 2.

152 The relative risk ratio (difference-in-differences) was 0.99 (95% CI

153 en led to high bias and low precision of the risk ratio due to extreme losses in study size and numbe

154 en led to high bias and low precision of the risk ratio due to extreme losses in study size and numbe

155 We then provide risk ratio equations for natural direct and indirect eff

156 Adjusted risk ratio estimates of racial disparities from complete

157 required a rare disease assumption for valid risk ratio estimation, but it was later realized that ra

158 .24-1.61; P = 1.7 x 10-7), respectively; the risk ratio for >=1 diagnosis of a lower respiratory illn

159 lative to annual school-based treatment, the risk ratio for annual community-wide treatment was 0.59

160 For death, the risk ratio for any type of surgery was 0.77 (95% CI = 0.

161 When adjusted for confounders, the risk ratio for development of the primary outcome was 0.

162 Risk ratio for dichotomous outcome and standardized mean

163 ponding age- and sex-adjusted genetic causal risk ratio for KIV-2 number of repeats was 1.20 (95% CI:

164 The risk ratio for recurrence by week 24 (also calculated wi

165 The adjusted risk ratio for the total effect of HDP on SMM was 2.55 (

166 The benefit-risk ratio for the vaccinated children is 85 000 (4900-5

167 burden among children younger than 15 years (risk ratio for those younger than 15 years vs those aged

168 For FUT2 SNP rs601338, the risk ratios for >=1 bout of diarrhea during ages 6-12 mo

169 We calculated risk ratios for all-cause mortality, combined MACE event

170 om-effects model was used to pool calculated risk ratios for all-cause mortality.

171 n body mass index was associated with causal risk ratios for aortic valve stenosis and replacement, r

172 For study-level meta-analysis, we calculated risk ratios for binary outcomes and standardised mean di

173 l) lower LDL cholesterol was associated with risk ratios for cardiovascular and all-cause mortality o

174 hreitol and glutathione assays drives higher risk ratios for certain cardiorespiratory outcomes than

175 Bivariate analysis estimated risk ratios for maternal and adverse outcomes.

176 We present benefit-risk ratios for routine childhood immunisation, with 95%

177 Risk ratios for the association between these outcomes a

178 In the Truven Health database, risk ratios for the pregnancy outcomes in women experien

179 c was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle

180 ccinated children is considered, the benefit-risk ratio is 3000 (182-21 000).

181 rt, whereas BRCAPRO and BCRAT underpredicted risk (ratio of expected cases to observed cases 1.05 [95

182 well calibrated, but BRCAPRO underpredicted risk (ratio of expected to observed cases 1.17 [95% CI 0

183 ng from 12 through 24 months with a relative risk ratio of 1.51 (95% CI 1.21, 1.88).

184 nts demonstrated a statistically significant risk ratio of 1.76 and 1.90 for inappropriate treatment,

185 n surgical ICUs, a statistically significant risk ratio of 2.59 was calculated for noninfectious or n

186 with no vaccination, resulting in a benefit-risk ratio of 369:1 (160:1-895:1).

187 The 5-year risk ratio of death associated with HF development 5 yea

188 usal analyses in the Copenhagen studies, the risk ratio of disease for a 1 mmol/l higher LDL-C was 1.

189 tial implications for optimizing the benefit/risk ratio of glucocorticoids in the clinic.

190 Risk ratio of good functional outcome after any type of

191 measurement error is itself assessed as the risk ratio of the controlled direct effect of the exposu

192 Using multinomial logistic regression, risk ratios of > +0.5 diopter (D) hyperopic and > 0.5 D

193 ut not significantly in the EAAA group, with risk ratios of 0.93 [CI: 0.82, 1.04, p=0.21] and 0.92 [C

194 on to estimate adjusted risk differences and risk ratios of long-term opioid use comparing those rece

195 We calculated the risk ratios or standardized mean difference of outcomes,

196 .9 per 1,000 births (95% CI: 3.7, 10.0), and risk ratios ranged from 1.12 (95% CI: 1.02, 1.23) to 2.9

197 venous access ports with the optimal benefit/risk ratio remains unclear.

198 Benefit-risk ratios (rotavirus gastroenteritis deaths prevented

199 ratively between PE cases and controls using risk ratio (RR) (95% CI) plus multivariate analysis.

200 ociated with a significant reduction in SSI [risk ratio (RR) 0.51, 95% confidence interval (CI) 0.46-

201 nificantly reduced transfusion rates by 39% [risk ratio (RR) 0.61, 95% confidence interval (CI) 0.55-

202 ed with a reduced risk of TTC contamination [risk ratio (RR) = 0.25, p < 0.001] and reported diarrhea

203 ht was associated with underweight (marginal risk ratio (RR) = 1.18, 95% confidence interval (CI): 1.

204 s increased with opioid prescription [1-3 d, risk ratio (RR) = 2.46, 95% CI = 1.31-5.78; 4-6 d, RR =

205 We meta-analysed the risk ratio (RR) for major vascular events (a composite o

206 The main outcome measure was the risk ratio (RR) for major vascular events associated wit

207 iance weighted analysis was used to obtain a risk ratio (RR) for the causal relation between circulat

208 as 18% with CDDP and 26% with AC, yielding a risk ratio (RR) of 0.70 (90% CI, 0.39 to 1.2).

209 for longitudinal studies that evaluated the risk ratio (RR) of cardiovascular disease in people with

210 credible interval [CrI] 0.009-0.15) and the risk ratio (RR) of seroconversion after three doses of b

211 NCs) were associated with higher prevalence [risk ratio (RR) per interquartile range (IQR) increase =

212 The prespecified noninferiority margin for risk ratio (RR) was 1.40.

213 The risk ratio (RR) was combined with country-specific UNAID

214 O danger signs compared with SpO2 >= 90%: HC Risk Ratio (RR), 9.37 (95% CI: 2.17-40.4, p = 0.003); CH

215 ng syndrome at 3 to 6 months [8.1% vs 32.4%; risk ratios (RR) 0.36, 95% CI, 0.21-0.60] and 12 to 24 m

216 and HIV transmission risk factor, estimated risk ratios (RR) and 95% confidence intervals (CI) for R

217 er as the unit of analysis, the association (risk ratios (RR) and 95% confidence intervals (CI)) betw

218 (RD) between control and pNPWT patients and risk ratios (RR) for SSI were obtained using random effe

219 The risk ratios (RR) for the primary outcome (ICH) and secon

220 using the inverse variance method for pooled risk ratios (RR) or odds ratios (OR) and evaluated stati

221 Estimates of risk ratios (RR), standardised mean differences, 95% con

222 Meta-analysis outcomes were summarised as risk ratios (RR).

223 -intervention areas by 88% with light traps (risk ratio [RR] 0.12, 95% CI 0.07-0.21, p < 0.001) and 9

224 SM significantly reduced the risk of stroke (risk ratio [RR] 0.24, 95% CI 0.08-0.68).

225 with reductions in P falciparum prevalence (risk ratio [RR] 0.27, 95% CI 0.17-0.44), anaemia (0.77,

226 women in the placebo plus misoprostol group (risk ratio [RR] 0.73, 95% CI 0.54-0.99; p=0.043).

227 with pregnancies beyond 20 weeks' gestation (risk ratio [RR] 0.80, 95% CI 0.61-1.06; p=0.121).

228 Intensive MDA had no effect on wheezing (risk ratio [RR] 1.11, 95% confidence interval [CI] 0.64-

229 patients in the high-dose indometacin group (risk ratio [RR] 1.19, 95% CI 0.87-1.61; p=0.32).

230 odynamic therapy (3 trials, 93 participants, risk ratio [RR] 1.42 [95% confidence interval (CI), 0.65

231 al immunotherapy increased anaphylaxis risk (risk ratio [RR] 3.12 [95% CI 1.76-5.55], I(2)=0%, risk d

232 isk of CeD in patients with IBD vs controls (risk ratio [RR] 3.96; 95% confidence interval [CI] 2.23-

233 Prevalence of low birth weight (37.9%, risk ratio [RR] = 12.61; 95% confidence interval [CI], 8

234 cantly higher than for controls (60% vs 25%, risk ratio [RR] for mortality 0.54, 95% CI [0.40-0.70];

235 were associated with increased risk of ever (risk ratio [RR] high vs low [RR Q4 vs Q1], 1.70; 95% CI,

236 and responses to therapy (2 studies showed a risk ratio [RR] of 16; 95% confidence interval [CI]: 2.3

237 ing predicted total antibiotic use (adjusted risk ratio [RR] per doubling of urine culturing, 1.21; 9

238 18 of 429 patients (4.2%) from 2010 onward (risk ratio [RR], 0.176; 95% confidence interval, .112-.2

239 and 2.2%-36.4% for the control group; pooled risk ratio [RR], 0.24 [95% CI, 0.14-0.40]; 12 trials) an

240 reduced all-cause mortality (9.0% vs. 17.6%; risk ratio [RR], 0.52 [95% CI, 0.33 to 0.81]) and HF hos

241 5% confidence interval {CI}, -3.7% to -.1%]; risk ratio [RR], 0.60 [95% CI, .37-.98]).

242 ood of onset of perinatal depression (pooled risk ratio [RR], 0.61 [95% CI, 0.47-0.78]; 17 RCTs [n =

243 In placebo-controlled trials, tamoxifen (risk ratio [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials [n =

244 3]; P=0.001) and reduced short-term (30 day; risk ratio [RR], 0.86 [95% CI, 0.77-0.96]; P=0.008) but

245 ause mortality in normotensive participants (risk ratio [RR], 0.90 [95% CI, 0.85 to 0.95]) and cardio

246 the risk of having a detectable viral load (risk ratio [RR], 1.28; 95% confidence interval [CI], 1.0

247 ompared with the SLT group (26.2% vs. 16.9%; risk ratio [RR], 1.55; 95% confidence interval [CI], 1.2

248 ncrease in the proportion of cysts resolved (risk ratio [RR], 1.98; 95% confidence interval [CI], 1.0

249 % CI, 1.9-4.1), and the case-fatality ratio (risk ratio [RR], 16.5; 95% CI, 13.7-19.8) associated wit

250 iated with the presence of Prevotella amnii (risk ratio [RR], 2.21; 95% confidence interval [CI], 1.1

251 y in patients with nonbacteremia infections (risk ratio [RR], 21.9; 95% confidence interval [CI], 7.0

252 red with standard of care (0.8% versus 1.2%; risk ratio [RR]: 0.61, 95% confidence interval [CI]: 0.4

253 care arms (59.1% versus 60.7%, respectively; risk ratio [RR]: 0.97; 95% CI: 0.82-1.15; p = 0.754).

254 in the highest HEI quartile at age 14 years (risk ratio [RR]: 2.1, 95% confidence interval [CI]: 2.0,

255 to undergo primary laser barricade (relative risk ratio [RRR] 1.68, P < .001), primary SB (RRR 1.15,

256 5-6.84) and multiclade communities (relative risk ratio [RRR], 9.51; 95% CI, 4.36-20.73) were also as

257 The adjusted risk ratios (RRs) and 95% CIs for GWG below the IOM reco

258 We estimated risk ratios (RRs) and 95% CIs for the associations betwe

259 We calculated risk ratios (RRs) and 95% CIs to summarise results.

260 d log-linear binomial regression to estimate risk ratios (RRs) and 95% CIs.

261 and HIV transmission risk factor, estimated risk ratios (RRs) and 95% confidence intervals (CIs) for

262 n models with log link functions to estimate risk ratios (RRs) and 95% confidence intervals (CIs) for

263 nalyses using a bayesian framework to derive risk ratios (RRs) and risk differences along with 95% cr

264 Random effects DerSimonian-Laird risk ratios (RRs) for outcomes were calculated.

265 ession models to calculate category-specific risk ratios (RRs) or adjusted differences and 95% confid

266 Risk ratios (RRs) were calculated with adjustment for po

267 Weighted risk ratios (RRs) were obtained using modified Poisson r

268 Risk ratios (RRs) with 95% CIs were calculated using a r

269 Risk estimates are reported as risk ratios (RRs) with 95% confidence intervals (CIs).

270 Pooled prevalence, risk ratios (RRs), and 95% confidence intervals (CIs) we

271 by difference in means (MD) or expressed as risk ratios (RRs), and associations with outcomes expres

272 models with random intercepts, and computed risk ratios (RRs), odds ratios (ORs), and 95% confidence

273 We report treatment effects as median risk ratios (RRs), wherein a null effect equals 1, with

274 rates and compared by group as cohort study risk ratios (RRs).

275 effect of the exposure on the outcome on the risk ratio scale must be at least as large as the observ

276 may provide a more favorable benefit versus risk ratio than an NSAID regimen.

277 averted from measles outbreaks, the benefit-risk ratio to the households of vaccinated children is 3

278 We estimated risk ratios to analyze the predictive ability of the PBS

279 eatment was -3.8% (95% CI -9.2-0.9%) and the risk ratio was 0.8 (95% CI 0.6-1.1).

280 undergoing orthopedic surgery, the relative risk ratio was 0.84 (95% CI 0.75-0.95).

281 infection was 4.3% (95% CI 0.4-8.9%) and the risk ratio was 1.4 (95% CI 1.0-1.9).

282 The fully adjusted average risk ratio was 1.63 [95% CI 1.44-1.84].

283 The relative risk ratio was 2.4 (95% CI: 1.6, 3.4; P < .001) for PAS

284 d no association between IDTs and IS, or the risk ratio was close to unity.

285 The benefit-risk ratio was most favourable when the relative risk of

286 Key outcomes are presented as pooled risk ratio, weighted mean difference, and the correspond

287 Risk ratios were adjusted for male partner testing histo

288 Risk ratios were calculated to evaluate the association

289 Relative risk ratios were computed to test the association of IFV

290 Increased dose-dependent risk ratios were found regardless of disease activity le

291 Five-year risk ratios were lower for ischemic heart disease (1.3 [

292 Pooled risk ratios were obtained through random effect meta-ana

293 Risk ratios were similar across demographic and socioeco

294 and it yields an estimate of a standardized risk ratio where the target population is the exposed gr

295 640 patients (1.1%) in the enoxaparin group (risk ratio with multiple imputation, 0.25; 95% confidenc

296 tly after RAMIE (59%) compared to OTE (80%) [risk ratio with RAMIE (RR) 0.74; 95% confidence interval

297 alculate weighted mean differences (WMDs) or risk ratios with 95% CIs.

298 outcomes were calculated as Mantel-Haenszel risk ratios with 95% CIs.

299 We pooled risk ratios with 95% confidence intervals and assessed t

300 dised mean differences, mean differences, or risk ratios with 95% credible intervals (CrIs).